NCT00316927

A Randomized Phase III Trial of Dexamethasone and Aspirin (DA) Versus Dexamethasone, Diethylstilbestrol and Aspirin (DAS) in Locally Advanced or Metastatic Cancer of the Prostate - Immediate Versus Deferred Diethylstilbestrol

Completed Phase 3 Last updated 25 June 2013

What this trial tests

Phase 3 trial testing acetylsalicylic acid in Prostate Cancer in 260 participants. Completed in 1 April 2007.

Timeline

1 December 2002

1 April 2007

Quick facts

Lead sponsor	St. Bartholomew's Hospital
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Primary purpose	treatment
Enrollment	260
Start date	1 December 2002
Estimated completion	1 April 2007
Sites	15 locations across United Kingdom

Drugs / interventions tested

• acetylsalicylic acid (acetylsalicylic acid) — full drug profile →
• dexamethasone (dexamethasone) — full drug profile →
• diethylstilbestrol (DIETHYLSTILBESTROL) — full drug profile →

Conditions studied

• Prostate Cancer — all drugs for Prostate Cancer →

Sponsor

St. Bartholomew's Hospital

Who can join

18 and older, male only, with Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

• Prostate-specific antigen (PSA) response

Sponsor's own description

RATIONALE: Giving dexamethasone together with aspirin and diethylstilbestrol may be effective in lowering prostate-specific antigen levels and may slow or stop the growth of prostate cancer. It is not yet known which schedule of dexamethasone, aspirin, and diethylstilbestrol is more effective in treating prostate cancer.

PURPOSE: This randomized phase III trial is studying dexamethasone and aspirin when given together with two different schedules of diethylstilbestrol to compare how well they work in treating patients with locally advanced or metastatic prostate cancer.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

1. Prostate Cancer Review: Genetics, Diagnosis, Treatment Options, and Alternative Approaches.
   Sekhoacha M, Riet K, Motloung P, Gumenku L, et al · · 2022 · cited 539× · PMID 36080493 · DOI 10.3390/molecules27175730
2. Metabolic rewiring in the promotion of cancer metastasis: mechanisms and therapeutic implications.
   Wei Q, Qian Y, Yu J, Wong CC. · · 2020 · cited 145× · PMID 32839493 · DOI 10.1038/s41388-020-01432-7
3. Drug Repositioning for Effective Prostate Cancer Treatment.
   Turanli B, Grøtli M, Boren J, Nielsen J, et al · · 2018 · cited 67× · PMID 29867548 · DOI 10.3389/fphys.2018.00500
4. A comprehensive AI-driven analysis of large-scale omic datasets reveals novel dual-purpose targets for the treatment of cancer and aging.
   Pun FW, Leung GHD, Leung HW, Rice J, et al · · 2023 · cited 21× · PMID 37888486 · DOI 10.1111/acel.14017
5. Overcoming Drug Resistance in Advanced Prostate Cancer by Drug Repurposing.
   Bahmad HF, Demus T, Moubarak MM, Daher D, et al · · 2022 · cited 16× · PMID 35225948 · DOI 10.3390/medsci10010015
6. Prostate cancer stem cells and their targeted therapies.
   Su H, Huang L, Zhou J, Yang G. · · 2024 · cited 5× · PMID 39175878 · DOI 10.3389/fcell.2024.1410102
7. Signalling pathways in a nutshell: from pathogenesis to therapeutical implications in prostate cancer.
   Goncharov AP, Dicusari Elissaiou C, Ben Aharon Farzalla E, Akhvlediani G, et al · · 2025 · cited 2× · PMID 40372974 · DOI 10.1080/07853890.2025.2474175